Literature DB >> 22275249

KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy.

Sarah Weckhuysen1, Simone Mandelstam, Arvid Suls, Dominique Audenaert, Tine Deconinck, Lieve R F Claes, Liesbet Deprez, Katrien Smets, Dimitrina Hristova, Iglika Yordanova, Albena Jordanova, Berten Ceulemans, An Jansen, Danièle Hasaerts, Filip Roelens, Lieven Lagae, Simone Yendle, Thorsten Stanley, Sarah E Heron, John C Mulley, Samuel F Berkovic, Ingrid E Scheffer, Peter de Jonghe.   

Abstract

OBJECTIVE: KCNQ2 and KCNQ3 mutations are known to be responsible for benign familial neonatal seizures (BFNS). A few reports on patients with a KCNQ2 mutation with a more severe outcome exist, but a definite relationship has not been established. In this study we investigated whether KCNQ2/3 mutations are a frequent cause of epileptic encephalopathies with an early onset and whether a recognizable phenotype exists.
METHODS: We analyzed 80 patients with unexplained neonatal or early-infantile seizures and associated psychomotor retardation for KCNQ2 and KCNQ3 mutations. Clinical and imaging data were reviewed in detail.
RESULTS: We found 7 different heterozygous KCNQ2 mutations in 8 patients (8/80; 10%); 6 mutations arose de novo. One parent with a milder phenotype was mosaic for the mutation. No KCNQ3 mutations were found. The 8 patients had onset of intractable seizures in the first week of life with a prominent tonic component. Seizures generally resolved by age 3 years but the children had profound, or less frequently severe, intellectual disability with motor impairment. Electroencephalography (EEG) at onset showed a burst-suppression pattern or multifocal epileptiform activity. Early magnetic resonance imaging (MRI) of the brain showed characteristic hyperintensities in the basal ganglia and thalamus that later resolved.
INTERPRETATION: KCNQ2 mutations are found in a substantial proportion of patients with a neonatal epileptic encephalopathy with a potentially recognizable electroclinical and radiological phenotype. This suggests that KCNQ2 screening should be included in the diagnostic workup of refractory neonatal seizures of unknown origin.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275249     DOI: 10.1002/ana.22644

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  146 in total

1.  De Novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy.

Authors:  Kazuyuki Nakamura; Hirofumi Kodera; Tenpei Akita; Masaaki Shiina; Mitsuhiro Kato; Hideki Hoshino; Hiroshi Terashima; Hitoshi Osaka; Shinichi Nakamura; Jun Tohyama; Tatsuro Kumada; Tomonori Furukawa; Satomi Iwata; Takashi Shiihara; Masaya Kubota; Satoko Miyatake; Eriko Koshimizu; Kiyomi Nishiyama; Mitsuko Nakashima; Yoshinori Tsurusaki; Noriko Miyake; Kiyoshi Hayasaka; Kazuhiro Ogata; Atsuo Fukuda; Naomichi Matsumoto; Hirotomo Saitsu
Journal:  Am J Hum Genet       Date:  2013-08-29       Impact factor: 11.025

2.  KCNQ2 Epileptic Encephalopathy in Early Infancy.

Authors:  Ananthanarayanan Kasinathan; Naveen Sankhyan; Pratibha Singhi
Journal:  Indian J Pediatr       Date:  2017-06-20       Impact factor: 1.967

Review 3.  Genetic Testing in Pediatric Epilepsy.

Authors:  Tristan T Sands; Hyunmi Choi
Journal:  Curr Neurol Neurosci Rep       Date:  2017-05       Impact factor: 5.081

Review 4.  The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.

Authors:  Davide Mei; Elena Parrini; Carla Marini; Renzo Guerrini
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

Review 5.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 6.  Subcellular localization of K+ channels in mammalian brain neurons: remarkable precision in the midst of extraordinary complexity.

Authors:  James S Trimmer
Journal:  Neuron       Date:  2015-01-21       Impact factor: 17.173

7.  Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.

Authors:  Bopanna I Kalappa; Heun Soh; Kevin M Duignan; Takeru Furuya; Scott Edwards; Anastasios V Tzingounis; Thanos Tzounopoulos
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

8.  Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy.

Authors:  Mark A Corbett; Susannah T Bellows; Melody Li; Renée Carroll; Silvana Micallef; Gemma L Carvill; Candace T Myers; Katherine B Howell; Snezana Maljevic; Holger Lerche; Elena V Gazina; Heather C Mefford; Melanie Bahlo; Samuel F Berkovic; Steven Petrou; Ingrid E Scheffer; Jozef Gecz
Journal:  Neurology       Date:  2016-10-12       Impact factor: 9.910

Review 9.  Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.

Authors:  Snezana Maljevic; Holger Lerche
Journal:  J Neurol       Date:  2012-11-11       Impact factor: 4.849

Review 10.  Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.

Authors:  Niyathi Hegde Shah; Elias Aizenman
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.